NCT06535399View on ClinicalTrials.gov

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

October 11, 2025

Study Completion Date

October 11, 2025

Conditions
Hepatic ImpairmentHealthy Volunteers
Interventions
DRUG

BMS-986369

Specified dose on specified days

Trial Locations (6)

32809

WITHDRAWN

Local Institution - 0005, Orlando

RECRUITING

Orlando Clinical Research Center, Orlando

78215

WITHDRAWN

Local Institution - 0006, San Antonio

RECRUITING

Texas Liver Institute, San Antonio

85225

RECRUITING

Arizona Liver Health, Chandler

WITHDRAWN

Local Institution - 0004, Chandler

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT06535399 - Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment | Biotech Hunter | Biotech Hunter